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oronary Multidetector
omputed Tomography
New Standard
or Preoperative Risk Assessment?*
do Hoffmann, MD, PHD,†‡
ichael Shapiro, DO†
oston, Massachusetts
or investigators interested in cardiovascular disease, these
re exciting times. It is rare that a new technology with the
otential to revolutionize the understanding and manage-
ent of a major disease process is introduced. For coronary
rtery disease (CAD), it might be that time, because
ultidetector computed tomography (MDCT) is a fast,
oninvasive, and robust method for visualization of the
ntire coronary artery tree in a single breath-hold. The
esearch activity over the last five years, bearing numerous
ublications suggesting the feasibility of coronary MDCT
o detect and characterize coronary artery stenosis, lays the
oundation for an unprecedented opportunity to: 1) enhance
ur understanding of the natural history of CAD, and 2)
xplore the potential of coronary MDCT to improve patient
anagement by means of cost and/or risk reduction.
See page 2020
he study by Gilard et al. (1) in this issue of the Journal is
ne of the first studies to address the latter. The primary end
oint of this blinded, observational cohort study was to
etermine the number of invasive angiograms that could be
voided before aortic valve replacement (AVR) by imple-
entation of a preoperative coronary MDCT. The results
ertainly demonstrate the potential of coronary MDCT to
eliably exclude the presence of coronary stenosis (sensitivity
nd negative predictive value 100%) in this patient cohort
iven an Agatston score 1,000. Although intriguing, this
esearch represents an initial assessment of a new technology
n a specific subset of patients. Thus, it might be helpful to
onsider the process of drug approval as an analogy in order
o determine the level of scientific evidence that is necessary
efore performing coronary MDCT routinely as part of the
reoperative management of patients with severe aortic
tenosis.
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Radiology, Massachusetts General Hospital, HarvardM
edical School, Boston, Massachusetts; and the ‡Harvard School of Public Health,
oston, Massachusetts.Feasibility studies demonstrating the accuracy and repro-
ucibility of a new technology are a necessary first step in
ssessing its clinical utility. In addition, there should be a
ompelling rationale for its implementation in the clinical
rena. This situation is typically found when the current
trategy for a specific clinical condition is imperfect, leaving
nough room for improvement in either patient safety or
ost-effectiveness. If both of these conditions are met,
bservational studies can determine whether the selected
atient population and the clinical end points are appropri-
te. These studies often also permit a preliminary assess-
ent of safety, cost, and cost effectiveness—information
hat is crucial to justify costly randomized diagnostic trials as
he final step of the process. Only validation at this level will
ventually enable the practice of evidenced-based medicine,
ermit recommendations by professional societies, and un-
quivocally justify reimbursement by third party payers.
If we apply these principles to the technology and clinical
pplication at hand, there are more than 35 studies that have
emonstrated the high sensitivity and specificity of both 16-
nd 64-slice MDCT for the detection of coronary stenosis
2). The fact that all studies thus far have been performed at
ingle centers in a very specific patient subsets remains a
imitation, and a multicenter trial, which has yet to be
erformed, is warranted.
Current patient management requires invasive coronary
ngiography primarily to exclude the presence of significant
oronary artery stenosis. Echocardiography is the method of
hoice to diagnose the severity of aortic stenosis and provides
ccurate information regarding valve morphology, LV func-
ion, and hemodynamic significance. Thus, the opportunity to
on-invasively exclude significant CAD provides a compel-
ing rationale for using coronary MDCT before AVR.
ence, the stage is set for the current study.
Three pieces of information are crucial to assess the
otential of coronary MDCT to improve safety and cost-
ffectiveness of the current preoperative workup in patients
cheduled for AVR:
. Prevalence of significant CAD in this population (i.e.,
how many angiograms can be avoided if the new
technique is perfect); this determines the maximum
benefit that can be achieved
. Accuracy of coronary MDCT to detect significant CAD
in exams with optimal image quality
. Fraction of non-diagnostic coronary MDCTs due to
impaired assessability of coronary segments with severe
calcification or motion artifacts.
The current study was performed in a French patient
opulation that had a low prevalence of CAD (20%). The
ensitivity and negative predictive value were 100%, the
pecificity was 80%, and the positive predictive value was
5% for coronary MDCT to identify a significant coronary
tenosis in patients with diagnostic examinations. CoronaryDCT was non-diagnostic in patients with an Agatston
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Editorial Comment May 16, 2006:2025–6core 1,000 (approximately 20%), rendering the following
ypothetical scenario for 100 patients with severe aortic
tenosis scheduled for AVR.
First, according to this algorithm, all 100 patients would
ndergo screening for coronary artery calcification. Twenty
atients would have an Agatston score of 1,000 and would
o on to invasive coronary angiography. The remaining 80
atients would undergo contrast enhanced MDCT. All
atients with significant CAD (n  16) would be correctly
dentified, but a significant coronary stenosis would be
rroneously diagnosed in 17 patients (specificity 80%).
ubsequently, patients with an Agatston score1,000 (n 
0), true positive CAD patients (n 16), and false positives
n  17) would undergo cardiac catheterization. Compar-
son of traditional standard of care (assuming all patients
ndergo invasive angiography) versus coronary MDCT-
uided decision-making yields a total savings of 47 invasive
ngiograms in the MDCT arm.
Although this analysis reflects the French population, the
ituation in the U.S. is different, where patients undergoing
VR are older, severe coronary calcification is found more
requently (approximately 25%), and the prevalence of CAD
s higher (approximately 60%) (3). In this population,
pproximately 25 patients would be expected to have an
gatston score 1,000 and only 75 patients would undergo
ontrast-enhanced MDCT. All patients with significant
AD (n  45) would be correctly identified, but a signif-
cant coronary stenosis would be erroneously diagnosed in
2 patients (specificity 80%). Subsequently, the patients
ith an Agatston score 1,000 (n  25), true positive
AD patients (n  45), and false positives (n  12) would
ndergo cardiac catheterization. Thus, coronary MDCT
ould yield a total savings of only 18 invasive angiograms in
he MDCT arm.
Although the data provided by Gilard et al. (1) clearly
upport the notion that coronary MDCT might be benefi-
ial for the preoperative management of patients with aortic
tenosis, the two aforementioned scenarios demonstrate the
ignificance of the prevalence of CAD and thus the patient
opulation as to whether coronary MDCT might improve
he safety and cost-effectiveness of the current standard of
are. It also becomes evident that severe coronary calcifica-
ion is currently a limiting factor, and thus the eliminationf calcium blooming artifacts is of utmost importance for
he success of coronary MDCT. Whereas the authors
erformed a receiver-operator characteristic analysis on
heir own data, which suggested a threshold of an Agatston
core 1,000 to be linked to non-diagnostic examinations,
his observation is limited, because no prospective evalua-
ion has been performed. In fact, a single large calcified
laque in a proximal location might prevent exclusion of a
ignificant coronary stenosis. It is conceivable that, until the
alcium problem has been solved, only a select group of
atients undergoing AVR in the U.S. (i.e., younger patients,
atients with bicuspid valves) might benefit from coronary
DCT.
Preoperative management is only one of many potential
pplications of coronary MDCT but exemplifies the larger
hallenge ahead of us: to improve physicians’ ability to make
nformed decisions and conduct evidence-based medicine
ith coronary MDCT.
There is now a window of opportunity to provide these
ata and to potentially demonstrate that coronary MDCT
mproves patient management in terms of diagnostic accu-
acy, clinical decision-making, and cost effectiveness. Be-
ause this window might be narrow, these ambitious goals
ay only be achieved in a major collaborative effort between
ardiologists, radiologists, and public health researchers.
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